Niacin in the metabolic syndrome: More risk than benefit?

Nature Clinical Practice Endocrinology and Metabolism

Volumn 2, Issue 6, 2006, Pages 300-301

  Ginsberg, Henry N ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFICACY; DYSLIPIDEMIA; GLYCEMIC CONTROL; HEALTH PROGRAM; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

BLOOD GLUCOSE; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; NIACIN; RISK ASSESSMENT;

EID: 33745069642     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0199     Document Type: Note

References (10)

1. th anniversary review. J Int Med 258: 94-114
2. Canner PL et al. (1986) Fifteen-year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 8: 1254-1255
3. Brown BG et al. (2001) Simvastatin and niacin, antioxidant vitamins or the combination for the prevention of coronary disease. N Engl J Med 345: 1583-1592
4. Tunaru S et al. (2003) PUMA-G and HM74 are receptors for nicotinic acid and mediate its antilipolytic effect. Nat Med 9: 352-355
5. Vega GL et al. (2005) Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol 95: 1309-1313
6. McCulloch DK et al. (1991) Effect of nicotinic acid-induced insulin resistance on pancreatic β cell function in normal and streptozocin-treated baboons. J Clin Invest 87: 1395-1401
7. Elam MB et al. (2000) Effects of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: a randomized trial. JAMA 284: 1263-1270
8. Grundy SM et al. (2002) Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med 162: 1568-1576
9. Canner PL et al. (2005) Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 95: 254-257
10. Zhao XQ et al. (2003) Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol 93: 307-312